ACC.24: The TACT2 Trial

ACC 24 - In this video, Dr Gervasio L Lamas (Mount Sinai Medical Center, US) joins us onsite to discuss the findings from the TACT2 study of chelation therapy in post-myocardial infarction patients with diabetes (NCT02733185).
The Trial to Assess Chelation Therapy 2 (TACT2) study is a randomized, double blind factorial clinical trial, aiming to determine if chelation-based strategy increases the time to the first occurrence of all-cause mortality, myocardial infarction, stroke, coronary revascularization or hospitalisation for unstable angina as compared to placebo. This is a 2x2 factorial trial, testing 40-weekly edetate disodium-based chelation infusions and twice daily high-dose oral multivitamins and minerals. 1000 patients with diabetes were enrolled into the study.
Findings showed that EDTA chelation produced a more than 60% reduction in blood lead levels, however, it did not result in a significant clinical benefit on the primary or secondary endpoints, or on all-cause mortality.
Recorded onsite at the ACC Conference in Atlanta, 2024.
Visit Radcliffe Cardiology: www.radcliffec...
Visit Radcliffe Vascular: www.radcliffev...
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on X: x.com/radcliff...